Evidence map›Paper›PMID 31482415›Full record

ArticleMolecular imaging and biology2020

Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia.

Manuela Ventura, Nicholas Bernards, Raquel De Souza, Inga B Fricke, Bart S Hendriks, Jonathan B Fitzgerald, Helen Lee, Stephan G Klinz, Jinzi Zheng

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Novel Tracers and Radionuclides in PET Imaging.Radiologic clinics of North America · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Manuela VenturaTECHNA Institute for the Advancement of Technology for Health, University Health Network, Toronto, Ontario, Canada.
Nicholas BernardsTECHNA Institute for the Advancement of Technology for Health, University Health Network, Toronto, Ontario, Canada.
Raquel De SouzaTECHNA Institute for the Advancement of Technology for Health, University Health Network, Toronto, Ontario, Canada.
Inga B FrickeTECHNA Institute for the Advancement of Technology for Health, University Health Network, Toronto, Ontario, Canada.
Bart S HendriksMerrimack Pharmaceuticals, Inc., Cambridge, MA, USA.
Jonathan B FitzgeraldMerrimack Pharmaceuticals, Inc., Cambridge, MA, USA.
Helen LeeMerrimack Pharmaceuticals, Inc., Cambridge, MA, USA.
Stephan G KlinzMerrimack Pharmaceuticals, Inc., Cambridge, MA, USA.
Jinzi ZhengTECHNA Institute for the Advancement of Technology for Health, University Health Network, Toronto, Ontario, Canada. jinzi.zheng@rmp.uhn.on.ca.ORCID http://orcid.org/0000-0002-7650-3910
Merrimack Pharmaceuticals (United States) · USUniversity Health Network · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHypoxia is linked to aggressiveness, resistance to therapy, and poor prognosis of pancreatic tumors. Liposomal irinotecan (nal-IRI, ONIVYDE®) has shown potential in reducing hypoxia in the HT29 colorectal cancer model, and here, we investigate its therapeutic activity and ability to modulate hypoxia in patient-derived orthotopic tumor models of pancreatic cancer. PROCEDURES: Mice were randomized into nal-IRI treated and untreated controls. Magnetic resonance imaging was used for monitoring treatment efficacy, positron emission tomography (PET) imaging with F-18-labelled fluoroazomycinarabinoside ([

resultsThe highly hypoxic OCIP51 tumors showed significant response following nal-IRI treatment compared with the less hypoxic OCIP19 tumors. [

conclusionsHypoxia modulation may play a role in nal-IRI's mechanism of action. Nal-IRI demonstrated greater anti-tumor activity in the more aggressive and hypoxic tumor model. Furthermore, hypoxia imaging provided early prediction of treatment response.

Indexed as

AnimalsCell HypoxiaFemaleFluorine RadioisotopesIrinotecanLiposomesLongitudinal StudiesMiceMice, Inbred NODMice, SCIDNitroimidazolesPancreatic NeoplasmsPositron-Emission TomographyRadiopharmaceuticalsTopoisomerase I InhibitorsTreatment OutcomeFluorine-18Fluorine Radioisotopesfluoroazomycin arabinosideIrinotecanLiposomesNitroimidazolesRadiopharmaceuticalsTopoisomerase I Inhibitors[18F]FAZAHypoxiaLiposomal irinotecanONIVYDEPancreatic cancer

Identifiers

PMID31482415
PMCPMC7782415
OpenAlexW2971960452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.